Summary KalVista is riding upon a successful phase 1 trial for DME, where KVD001 was well tolerated and signal of improved visual acuity followed after one single dose. Expect top-line results for its phase 2 clinical trial of KVD001 in 123 DME patients to be released in the second half of 2019. Merck is quite bullish on KalVista as shown …

A randomized, double-blind, placebo-controlled clinical trial found no benefit for a therapeutic HIV vaccine, but could offer researchers much needed insights for future cure efforts. The authors say their results represent yet another addition to the burgeoning body of evidence that therapeutic vaccination fails to help patients suppress HIV in the absence of antiretroviral therapy (ART). Although ART has provided …